Physician profile
John E Van Wye
NPI 1790776235
$11,115.41
in general payments reported to CMS, 2019-2025
29 companies · $1,140 in 2025
The $1,140 reported for 2025 was less than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $739 · 2020: $544 · 2021: $1,088 · 2022: $987 · 2023: $1,240 · 2024: $5,377 · 2025: $1,140.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,003 · Consulting Fee: $3,754.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,002.85 |
| Consulting Fee | $3,754.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $3,964.22 | 2019-2025 | |
| Glaxosmithkline, LLC. | $1,338.69 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals LP | $913.58 | 2019-2025 | Airsupra, Tezspire, Fasenra |
| Csl Behring | $760.18 | 2019-2025 | Haegarda, Hizentra |
| Genzyme Corporation | $668.18 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $628.22 | 2019-2025 | Dupixent |
| Amgen INC. | $400.60 | 2023-2025 | Tezspire |
| Genentech USA, INC. | $357.73 | 2019-2025 | Xolair |
| Takeda Pharmaceuticals U.S.A., INC. | $330.39 | 2021-2024 | Takhzyro, Cuvitru |
| Biocryst US Sales Co., LLC | $250.56 | 2021-2025 | Orladeyo |
| Grifols USA, LLC | $242.02 | 2019-2025 | Xembify |
| Ars Pharmaceuticals Operations, INC. | $234.86 | 2025 | Neffy |
| Pfizer INC. | $154.68 | 2019-2025 | |
| Alk-Abello, INC | $139.52 | 2019-2021 | |
| Optinose US, INC. | $121.26 | 2019-2024 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kaleo, INC. | $118.55 | 2019-2022 | |
| Pharming Healthcare, INC. | $104.40 | 2020-2024 | Ruconest |
| Hospira, INC. | $87.83 | 2021-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $70.00 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $47.71 | 2021-2023 | |
| Teva Pharmaceuticals USA, INC. | $43.59 | 2021 | |
| Biocryst Pharmaceuticals, INC. | $22.33 | 2020 | |
| Uswm, LLC | $20.34 | 2021 | |
| Abbvie INC. | $19.90 | 2022 | |
| Blueprint Medicines Corporation | $17.80 | 2025 | Ayvakit |
| Adma Biomanufacturing LLC | $16.52 | 2024 | |
| Circassia INC. | $16.38 | 2019 | |
| Galderma Laboratories, L.P. | $13.47 | 2025 | Nemluvio |
| Sunovion Pharmaceuticals INC. | $11.90 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Van Wye listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.